Wyatt Investment Research login

 
Forgot password? Not a Subscriber? - Start Here
 
 
HOMEWEEKLY NEWSLETTERMODEL PORTFOLIOSPECIAL REPORTSVIDEO UPDATESCUSTOMER SERVICE
 
 

Tag - Anik

 

 
Ian Wyatt

Stocks Trading Higher in Thursday Session

Stocks are trading higher as of press time, 2:00 P.M. Eastern Time. The Dow was up 52 points at 9,331, the Nasdaq was up 15 points to 1,984, and the S&P 500 had pushed over 1,000 to 1,005, up 9 points.

The Russell 2000, the composite index of leading small-cap stocks, was at 565, up nearly 4 points.

Advancers lead decliners on all three major U.S. exchanges by a margin of 2 to 1 for the NYSE and AMEX and 5 to 4 on the Nasdaq.

Small-cap price gainers with over 1 million shares traded include Anika Therapeutics (Nasdaq:ANIK), up 36%; Reddy Ice Holdings (NYSE:FRZ), up 26%; and Renesola Limited (NYSE:SOL), up 18%.

*****"The question is not whether the dollar will weaken over time, but how it will weaken…"

That's what the CEO of bond giant PIMCO, Mohamed El-Erian, had to say as central bankers from around the world gather in Jackson Hole, Wyoming. They'll review the various strategies implemented to stave off the global financial crisis and discuss what they'll do as the world economy recovers.

In Ben Bernanke's case, we probably already know what he will, or won't, do. 

A student of the Great Depression, Bernanke understands how damaging a deflationary spiral can be. Spending slows, unemployment rises, businesses fail. And like a negative feedback loop, failing business leads to even higher unemployment and less spending.

Quite simply, Bernanke believes that, between inflation and deflation, inflation is easier to fight. So we should all expect Bernanke to allow, even invite, inflation to help rescue the U.S. economy.

*****Make no mistake, deflation is still a threat. So long as unemployment is on the rise, spending and prices will likely decline. And today's surprise jump in new unemployment claims should serve notice that, despite recent improvements in some unemployment numbers, the trend for unemployment numbers is still up.

The housing market has shown some improvement recently. But what will happen when the summer home-buying season ends? Inventories will rise, and any individual homeowners wanting to sell will be competing against fire sale foreclosure properties. Who's going to buy it seems likely that prices will be lower next spring? It's the sickening reverse of what we saw earlier this decade where people bid up home prices because they knew they needed to buy now before prices go higher. If they now believe prices will be lower in the future and they're not under some pressure to move, then they'll wait. And this will further drive down housing prices and will definitely continue to affect new home construction which will affect employment (negatively), and, well, you get the cycle.

*****It's widely believed that a weaker U.S. dollar will ultimately be good for the U.S. economy. That's because a weaker dollar makes U.S. exports more competitive. And the logic goes that more competitive exports could spark a revitalization of American manufacturing sector and put people back to work.

Of course, any such manufacturing renaissance will be funded by the deterioration of our wealth. In essence, the weak dollar will be a silent tax, a massive redistribution of wealth from the middle and upper class to the manufacturing sector.

What's more, the decline in purchasing power of the dollar is virtually unnoticeable. Unless of course, you travel overseas. The euro, currently fetching $1.42, could trade for $1.60 before the end of the year. It was as low as $0.90 earlier this decade.

No one will argue that a stronger manufacturing sector will be ultimately good for America. But it comes at a cost. The global playing field will level. And that means your investments will be the key to staying ahead of the game.

*****So whether you choose to subscribe to one of my advisory services and discover how we're beating the market and inflation investing in commodities or small cap stocks, or you prefer to stay with a trusted advisor or manage your own accounts, it is absolutely critical for your financial well-being that you remain diligent and keep the prevailing economic trends in mind when investing. While you can sometimes go against a trend and occasionally make a quick buck, the typical individual investor needs to follow the trends for long term portfolio profitability.

Until tomorrow,

Ian Wyatt
Editor
Daily Profit

P.S. Speaking of trends, have you been following what's happening China? After an enormous run-up since last fall Chinese stocks are pulling back. If you missed the last run-up this is you second chance to get it. I've recently added three high quality long term China-based holdings to my SmallCapInvestor.com PRO portfolio. To find out more about them and get the full research report CLICK HERE.

P.P.S. My book The Small-Cap Investor: Secrets to Winning Big with Small-Cap Stocks is coming out on September 14 - visit www.smallcapbook.com to learn more. You can also follow me on http://twitter.com/ianwyatt 

Ian Wyatt is the Chief Investment Strategist of SmallCapInvestor.com and author of The Small-Cap Investor: Secrets to Winning Big with Small-Cap Stocks. You can learn more about his book and receive small-cap stock picks at www.smallcapbook.com.


[ More » ]
Claire Caldwell

World Heart, Anika Therapeutics and Standex International are among the biggest percentage gainers

World Heart Corp. (Nasdaq:WHRT), Anika Therapeutics Inc. (Nasdaq:ANIK) and Standex International Corp. (Nasdaq:SXI) are among the biggest percentage gainers in Thursday's trading among companies with market capitalizations under $1 billion.

Also included among the results: Regis Corp. (Nasdaq:RGS), Southern National Bancorp Of Virginia Inc. (Nasdaq:SONA), Exide Technologies (Nasdaq:XIDE), Shamir Optical Industry Ltd. (Nasdaq:SHMR) and Saga Communications Inc. (Nasdaq:SGA).
[ More » ]
Will Atkinson

Momenta Pharmaceuticals, Albany Molecular Research and Jaclyn lead small-cap percentage losers

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), Albany Molecular Research, Inc. (Nasdaq: AMRI) and Jaclyn, Inc. (AMEX: JLN)  are among the biggest percentage losers in Tuesday's trading among companies with market capitalizations under $500 million.

Here are today's biggest percentage losers:

[ More » ]
Will Atkinson

Leading Wednesday small-cap percentage gainers: PVF Capital Corp., SeaBright Insurance Holdings Inc., Semitool Inc.

PVF Capital Corp. (Nasdaq: PVFC), SeaBright Insurance Holdings, Inc. (Nasdaq: SEAB) and Semitool, Inc. (Nasdaq: SMTL) are among the biggest percentage gainers in Wednesday's trading among companies with market capitalizations under $500 million.

Here are today's biggest percentage gainers:

[ More » ]
Wyatt Research Staff

Thursday after hours

The following small-cap companies are among the newsmakers in after-hours trading Wednesday:

Shares of Dyax Corp. (Nasdaq: DYAX) skyrocketed by $1.70, or 42.5%, to $5.68 in after-hours trading today after the biopharmaceutical company announced positive late-stage trial results for DX-88, its treatment of hereditary angioedema (HAE), an inflammatory condition. Cambridge, Mass.-based Dyax says the findings should position the company to apply for regulatory approval. The drug currently has Fast Track Designation with the U.S. Food and Drug Administration. The latest results showed no drug-related serious adverse side effects and statistically significant improvement of symptoms in patients. Dyax was trading higher on unusually heavy volume of nearly 600,000 shares - more than twice its three-month average volume of 242,000.

SurModics Inc.’s (Nasdaq: SRDX) shares were up $0.07, or 0.2%, to $37.20 in after-hours trading on the news that the company had inked an expanded technology corporate agreement with St. Jude Medical Inc. (NYSE: STJ). Nearly 400,000 shares had changed hands by 5 p.m. ET – more than double the three-month average volume of 159,921 shares. Eden Prarie, Minn.-based SurModics and St. Jude’s plan to work together to commercialize new products being developed in St. Jude’s cardiovascular and cardiac rhythm management divisions.
[ More » ]